Post-surgery adjuvant treatment improves outcomes for HCC patients

A study of 649 hepatocellular carcinoma (HCC) patients revealed that those with triple positive tumor markers experienced significantly improved recurrence-free survival when receiving postoperative adjuvant therapy (30.0 months) compared to those who did not (19.6 months, p=0.019). The analysis also showed that the number of positive tumor markers was linked to various clinical and pathological characteristics, suggesting these markers can serve as effective predictors for selecting high-risk patients for tailored postoperative interventions.